Strides Pharma Science Limited on Tuesday announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Ltd, Singapore, has received approval for Ethacrynic Acid Tablets USP, 25 mg from the United States Food & Drug Administration (USFDA).
The product is a generic version of Edecrin Tablets, 25 mg, of Bausch Health Americas, Inc., the company said in a statement.
The product would be manufactured at the company’s flagship facility here and marketed by Strides Pharma Inc. in the US market, it said.
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
